Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily
Phase 3Completed 3 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HIV Infections
Conditions
HIV Infections
Trial Timeline
Apr 18, 2012 → Dec 16, 2013
NCT ID
NCT01568892About Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily is a phase 3 stage product being developed by Shionogi for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01568892. Target conditions include HIV Infections.
What happened to similar drugs?
20 of 20 similar drugs in HIV Infections were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01568892 | Phase 3 | Completed |
Competing Products
20 competing products in HIV Infections